Form 4: ADMA Biologics CEO Adam Grossman Reports Stock Transactions
SEC Form 4 Filing
Adam Grossman, CEO of ADMA Biologics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.
Summary
- On March 6, 2025, Adam Grossman, CEO of ADMA Biologics, had 56,438 common stock shares withheld at a price of $16.91 to cover tax obligations upon vesting of restricted stock units.
- Following this transaction, Grossman directly owns 2,097,363 shares of common stock.
- On March 7, 2025, an additional 29,513 shares were withheld at $17.02 per share, resulting in direct ownership of 2,067,850 shares.
- Grossman also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, indicating a neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CEO's stock ownership.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | 56,438 shares of common stock withheld for tax obligations at $16.91 per share. |
| 03/07/2025 | 29,513 shares of common stock withheld for tax obligations at $17.02 per share. |
| 03/10/2025 | Date of signature by Michael A. Goldstein as Attorney-in-fact for Adam S. Grossman. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.